CNP 520

Drug Profile

CNP 520

Alternative Names: AMG 520; CNP520

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antidementias
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 25 Jan 2017 CNP 520 receives Fast Track designation for Alzheimer's disease [PO,Capsule] in USA before January 2017
  • 13 Jun 2016 Phase-II/III clinical trials in Alzheimer's disease in Finland and Belgium (PO) (EudraCT2015-002715-15)
  • 01 Mar 2016 Novartis completes a phase II trial in Alzheimer's disease (In volunteers) in Netherlands, Germany, United Kingdom, Belgium and USA (NCT02576639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top